SUDOSCAN is a medical device company that specializes in the development of innovative devices to manage and care for diabetes and diseases that cause neuropathies. The company has a strong commitment to research and development, and as a result, has been involved in several research studies to evaluate the effectiveness of their products.

One such study was a multicenter trial conducted in 2018 to evaluate the utility of SUDOSCAN in the detection of diabetic neuropathy. The study involved 202 patients with type 2 diabetes and found that SUDOSCAN was a reliable and efficient tool for the early detection of diabetic neuropathy. The results of the study were published in the Journal of Diabetes and Its Complications and were well-received by the medical community.

In addition to research studies, SUDOSCAN has also been featured in several media outlets. In 2020, the company was featured in a news segment on CBS News, where they discussed the benefits of SUDOSCAN for early detection of diabetic neuropathy. The segment highlighted the ease and convenience of the test and emphasized its potential to improve patient outcomes.

SUDOSCAN is also actively involved in medical conferences and events. In 2021, the company participated in the American Diabetes Association’s virtual conference, where they presented the results of a study that demonstrated the efficacy of SUDOSCAN in monitoring the progression of diabetic neuropathy. The company has also participated in other medical events, such as the International Neuromodulation Society Congress and the International Diabetes Federation Congress.

Overall, SUDOSCAN has made significant contributions to the field of medical technology through their commitment to research, media, and events. Their innovative products have the potential to significantly improve patient outcomes and their active participation in medical conferences and events demonstrates their commitment to improving healthcare on a global scale.